BeyondSpring to acquire SEED Therapeutics for $35.4m.

BeyondSpring, a pharmaceutical company, agreed to acquire SEED Therapeutics, a biotechnology company, for $35.4m. “With this capital, BeyondSpring is strategically positioned to advance our 303 and 302 studies in Plinabulin combination with immune checkpoint inhibitors to registrational trials and explore business development partnerships to bring Plinabulin to cancer patients with limited treatment options. At the same time, retaining a substantial stake in SEED Therapeutics ensures that we remain part of its continued success in revolutionizing drug discovery,” Dr. Lan Huang, BeyondSpring Co-Founder, Chairman, and CEO.